Section Arrow
Quote
ENLV.NASDAQ
- Enlivex Therapeutics Ltd
Quotes are at least 15-min delayed:2026/01/04 22:16 EST
Regular Hours
Last
 0.7549
+0.0517 (+7.35%)
Day High 
0.77 
Prev. Close
0.7032 
1-M High
1.245 
Volume 
396.91K 
Bid
0.69
Ask
0.7677
Day Low
0.7034 
Open
0.7215 
1-M Low
0.66 
Market Cap 
163.82M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.78 
20-SMA 0.9 
50-SMA 0.96 
52-W High 2.1 
52-W Low 0.66 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.54/-0.78
Enterprise Value
164.12M
Balance Sheet
Book Value Per Share
0.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.